1.Evaluation of performance of disposable medical protective clothing for resistance to infective agent penetration
Ke-Yang LIU ; Yan FENG ; Juan ZHANG ; Yue NIU ; Dan QIN ; Yong-Fu HUANG ; Guang-Yong HU
Chinese Medical Equipment Journal 2024;45(5):16-21
Objective To evaluate the performance of the disposable medical protective clothing in blocking the penetration of infectious agents,in order to provide data support for the setting of such performance indexes when the GB 19082 is revised.Methods Totally 10 batches of different brands and models of protective clothing were selected,and tests were carried out for penetration resistance to synthetic blood,phage,wet microorganisms,dry microorganisms and contaminated liquid aerosol and particle filtration efficiency according to YY/T 0700-2008,YY/T 0689-2008,YY/T 0506.6-2009,GB 19082-2009,YY/T 0506.5-2009 and YY/T 1799-2020.Results There were 2 batches of protective clothing with anti-synthetic blood penetration performance level 2,3,4,5 and 6,respectively;all the protective clothing had the highest level 6 for anti-wet microorganisms penetration,part of whom had the levels for the resistance to phage penetration lower than those for preventing anti-synthetic blood penetration;all of the protective clothing had the particle filtration efficiencies higher than 95%,and had the highest level 3 for anti-dry microorganisms penetration;there're 5 batches of protective clothing with the highest level 3 for contaminated liquid aerosol penetration,1 batch with level 2 and the remained 4 batches with undetermined levels,which all had an average logarithmic reduction higher than 4.5 after penetration.Conclusion Particle filtration efficiency and resistance to phage penetration may be involved in the requirements for resistance to infective agent penetration in revised GB 19082 for evaluating the ability of protective clothing materials to block microorganisms in airborne particles and liquid contaminants.[Chinese Medical Equipment Journal,2024,45(5):16-21]
2.Interpretation of YY 1881-2023 Powered air-purifying respirator(PAPR)used in healthcare settings
Ke-Yang LIU ; Yong-Fu HUANG ; Guang-Yong HU
Chinese Medical Equipment Journal 2024;45(8):1-6
The standard YY 1881-2023 Powered air-purifying respirator(PAPR)used in healthcare settings was introduced in terms of development background,foreign and China's standards involved in during its development and settings of related product performance indicators,which was interpreted from the aspects of scope of application,classificantion and marking of targeted products and main performance requirements.References were provided for correct understanding of the standard terms and product development,manufacturing,inspection and etc.[Chinese Medical Equipment Journal,2024,45(8):1-6]
3.Interpretation of YY 1887-2023 Positive pressure protective clothing(PPPC)for medical use
Ke-Yang LIU ; Yong-Fu HUANG ; Guang-Yong HU
Chinese Medical Equipment Journal 2024;45(8):7-11
The standard YY 1887-2023 Positive pressure protective clothing(PPPC)for medical use was introduced in terms of development background and foreign and China's standards involved in during the standard development,which was interpreted from the aspects of scope of application,structural composition and main performancerequirements.References were provided for correct understanding of the standard terms and product development,manufacturing,inspection and etc.[Chinese Medical Equipment Journal,2024,45(8):7-11]
4.Interpretation of YY 1885-2023 Negative pressure isolators for transport of infectious patients
Ke-Yang LIU ; Yong-Fu HUANG ; Guang-Yong HU
Chinese Medical Equipment Journal 2024;45(8):12-15
The standard YY 1885-2023 Negative pressure isolators fortransport of infeectious patients was introduced in terms of development background,which was interpreted from the aspects of definition of terms,scope of application and performance requirements.References were provided for correct understanding of the standard terms and product development,manufac-turing,inspection and etc.[Chinese Medical Equipment Journal,2024,45(8):12-15]
5.Value of MRI Ovarian-Adnexal Reporting and Data System in Differentiating Benign and Malignant Ovarian-Adnexal Lesions
Wen-hao FU ; Xiao-xiao HU ; Meng-ya SUN ; Fan ZHANG ; Ke WANG ; Guang-lei TANG ; Jian GUAN
Journal of Sun Yat-sen University(Medical Sciences) 2023;44(1):99-105
ObjectiveTo explore the value of MRI ovarian-adnexal reporting and data system (O-RADS MRI) in differentiating benign and malignant ovarian-adnexal masses.MethodsTotally 146 patients (202 masses) with ovarian-adnexal lesions who underwent pelvic examination at 3.0 T MRI according to standardized scan protocol of O-RADS MRI and were pathologically confirmed in The First Affiliated Hospital of Sun Yat-sen University between January 2020 and February 2022 were retrospectively analyzed. Two radiologists classified the ovarian-adnexal masses as risk levels 1~5 according to O-RADS MRI and evaluated their consistency by Cohen’s kappa. Using pathological findings as the gold standard, the detection yield of malignant lesions with O-RADS MRI classification was analyzed. Sensitivity, specificity, accuracy, and the area under the receiver operating characteristic curve were calculated (cutoff for malignancy, score ≥ 4).ResultsOf 202 masses, 62 (30.7%) were malignant, 140 (69.3%) were benign. The two radiologists presented good agreement in O-RADS MRI classification of ovarian adnexal masses (Kappa=0.932). The malignancy rates of masses with scores of 1, 2, 3, 4 and 5 were 0%, 0%, 7.7%, 95%, 97.6%, respectively. Sensitivity, specificity, accuracy, and the area under the receiver operating characteristic curve were 96.8% (60/62), 98.6% (138/140), 98.0% (198/202), 0.977.ConclusionsO-RADS MRI yields high diagnostic efficiency for benign and malignant ovarian adnexal masses and its widespread implementation will improve communication between radiologists and clinicians, and facilitate optimal patient management. Therefore, O-RADS MRI warrants widespread use in clinical setting.
7.Practice and experience of preventing blindness using a mobile cataract operation vehicle in Shaanxi province for 25 years
Jing LI ; Ya-Guang HU ; Xiu-E SHI ; Yi GUO ; Jing GUO ; Yan-Nian HUI ; Xian-Fu YUE
International Eye Science 2022;22(11):1886-1891
The“14th Five-Year” National Eye Health Plan has been released and national eye health has risen as a national strategy. Cataract is the primary blinding eye disease in our country, which seriously affects the national eye health. Shaanxi Province, an old revolutionary base area in the western of China, has a relative lower socioeconomic level and about millions of people need to undergo cataract surgery. In 1996, multi-cooperation built the mobile ophthalmic operation vehicle — “Fuming No.1” to contribute the poverty alleviation initiative in Shaanxi Province. In the past 25a, “Fuming No.1” has taken the advantage of the convenience of mobile operation vehicles, implementing operations in rural, mountainous and old areas with weak medical services in Shaanxi Province. A total of more than 480 trips have been made, with a total mileage of more than 200 000 kilometers,covering 104 counties and districts in the province, and nearly 60 000 cases of cataract operations have been completed. “Fuming No.1” bring the light, relieve the pain for cataract patients and help them better fit the world. Furthermore, “Fuming No.1” also offers free operation and intraocular lens for more than 30 000 poor rural patients and reduces medical expenses by nearly 10 million yuan, which has obtained high praise and support from the patients and all walks of life. In addition, “Fuming No.1” is also a mobile training vehicle, which could improve the operation skills of ophthalmologists. In the process of teaching and training, the operations had also been completed with high quality. In view of the unbalanced economic development in our country, “Fuming No.1” will expand service projects, innovate work models, and continue to construct eye healthy in Shaanxi province, making greater contributions to consolidating the achievements of poverty alleviation.
8.Chemical synthesis of a synthetically useful L-galactosaminuronic acid building block.
Chun-Jun QIN ; Hong-Li HOU ; Mei-Ru DING ; Yi-Kuan QI ; Guang-Zong TIAN ; Xiao-Peng ZOU ; Jun-Jie FU ; Jing HU ; Jian YIN
Chinese Journal of Natural Medicines (English Ed.) 2022;20(5):387-392
Most bacterial cell surface glycans are structurally unique, and have been considered as ideal target molecules for the developments of detection and diagnosis techniques, as well as vaccines. Chemical synthesis has been a promising approach to prepare well-defined oligosaccharides, facilitating the structure-activity relationship exploration and biomedical applications of bacterial glycans. L-Galactosaminuronic acid is a rare sugar that has been only found in cell surface glycans of gram-negative bacteria. Here, an orthogonally protected L-galactosaminuronic acid building block was designed and chemically synthesized. A synthetic strategy based on glycal addition and TEMPO/BAIB-mediated C6 oxidation served well for the transformation of commercial L-galactose to the corresponding L-galactosaminuronic acid. Notably, the C6 oxidation of the allyl glycoside was more efficient than that of the selenoglycoside. In addition, a balance between the formation of allyl glycoside and the recovery of selenoglycoside was essential to improve efficiency of the NIS/TfOH-catalyzed allylation. This synthetically useful L-galactosaminuronic acid building block will provide a basis for the syntheses of complex bacterial glycans.
Carbohydrates
;
Glycosides
;
Oligosaccharides
;
Oxidation-Reduction
;
Polysaccharides/chemistry*
9.Chemical approaches towards installation of rare functional groups in bacterial surface glycans.
Chun-Jun QIN ; Mei-Ru DING ; Guang-Zong TIAN ; Xiao-Peng ZOU ; Jun-Jie FU ; Jing HU ; Jian YIN
Chinese Journal of Natural Medicines (English Ed.) 2022;20(6):401-420
Bacterial surface glycans perform a diverse and important set of biological roles, and have been widely used in the treatment of bacterial infectious diseases. The majority of bacterial surface glycans are decorated with diverse rare functional groups, including amido, acetamidino, carboxamido and pyruvate groups. These functional groups are thought to be important constituents for the biological activities of glycans. Chemical synthesis of glycans bearing these functional groups or their variants is essential for the investigation of structure-activity relationships by a medicinal chemistry approach. To date, a broad choice of synthetic methods is available for targeting the different rare functional groups in bacterial surface glycans. This article reviews the structures of naturally occurring rare functional groups in bacterial surface glycans, and the chemical methods used for installation of these groups.
Bacterial Infections
;
Humans
;
Polysaccharides/chemistry*
;
Structure-Activity Relationship
10.Efficacy and safety of Shenyankangfu Tablet, a Chinese patent medicine, for primary glomerulonephritis: A multicenter randomized controlled trial.
Jie WU ; Shu-Wei DUAN ; Hong-Tao YANG ; Yue-Yi DENG ; Wei LI ; Ya-Ni HE ; Zhao-Hui NI ; Yong-Li ZHAN ; Shan LIN ; Zhi-Yong GUO ; Jun ZHU ; Jing-Ai FANG ; Xu-Sheng LIU ; Li-Hua WANG ; Rong WANG ; Nian-Song WANG ; Xiao-Hong CHENG ; Li-Qun HE ; Ping LUO ; Shi-Ren SUN ; Ji-Feng SUN ; Ai-Ping YIN ; Geng-Ru JIANG ; Hong-Yu CHEN ; Wen-Hu LIU ; Hong-Li LIN ; Meng LIANG ; Lu MA ; Ming CHEN ; Li-Qun SONG ; Jian CHEN ; Qing ZHU ; Chang-Ying XING ; Yun LI ; Ji-Ning GAO ; Rong-Shan LI ; Ying LI ; Hao ZHANG ; Ying LU ; Qiao-Ling ZHOU ; Jun-Zhou FU ; Qiang HE ; Guang-Yan CAI ; Xiang-Mei CHEN
Journal of Integrative Medicine 2021;19(2):111-119
BACKGROUND:
Shenyankangfu Tablet (SYKFT) is a Chinese patent medicine that has been used widely to decrease proteinuria and the progression of chronic kidney disease.
OBJECTIVE:
This trial compared the efficacy and safety of SYKFT, for the control of proteinuria in primary glomerulonephritis patients, against the standard drug, losartan potassium.
DESIGN, SETTING, PARTICIPANTS AND INTERVENTION:
This was a multicenter, double-blind, randomized, controlled clinical trial. Primary glomerulonephritis patients, aged 18-70 years, with blood pressure ≤ 140/90 mmHg, estimated glomerular filtration rate (eGFR) ≥ 45 mL/min per 1.73 m
MAIN OUTCOME MEASURES:
The primary outcome was change in the 24-hour proteinuria level, after 48 weeks of treatment.
RESULTS:
A total of 735 participants were enrolled. The percent decline of urine protein quantification in the SYKFT group after 48 weeks was 8.78% ± 2.56% (P = 0.006) more than that in the losartan 50 mg group, which was 0.51% ± 2.54% (P = 1.000) less than that in the losartan 100 mg group. Compared with the losartan potassium 50 mg group, the SYKFT plus losartan potassium 50 mg group had a 13.39% ± 2.49% (P < 0.001) greater reduction in urine protein level. Compared with the losartan potassium 100 mg group, the SYKFT plus losartan potassium 100 mg group had a 9.77% ± 2.52% (P = 0.001) greater reduction in urine protein. With a superiority threshold of 15%, neither was statistically significant. eGFR, serum creatinine and serum albumin from the baseline did not change statistically significant. The average change in TCM syndrome score between the patients who took SYKFT (-3.00 [-6.00, -2.00]) and who did not take SYKFT (-2.00 [-5.00, 0]) was statistically significant (P = 0.003). No obvious adverse reactions were observed in any group.
CONCLUSION:
SYKFT decreased the proteinuria and improved the TCM syndrome scores of primary glomerulonephritis patients, with no change in the rate of decrease in the eGFR. SYKFT plus losartan potassium therapy decreased proteinuria more than losartan potassium therapy alone.
TRIAL REGISTRATION NUMBER
NCT02063100 on ClinicalTrials.gov.

Result Analysis
Print
Save
E-mail